Watson-Marlow has announced the beginning of construction on a US manufacturing facility, with first production planned for late 2022. The facility will be dedicated to products including peristaltic pumps, tubing, fluid path solutions and BioPure components.
The significant investment in expanding its manufacturing capacity is aimed to support the company’s future growth in the Americas.
Located in Devens, Massachusetts, USA, the 150,000 sqft facility will be located close to the Boston/Cambridge life sciences hub. The site will incorporate eight ISO14644-1 Class 7 cleanrooms, warehousing and offices, with space for two further cleanrooms within the initial footprint. With segregated cleanroom and non-cleanroom production capabilities, the facility will support regional customers across the pharmaceutical and biotechnology, medical diagnostics, and process industries.
“The new US facility is an important milestone in the Watson-Marlow company history and marks a significant commitment to serving our customers in the Americas region," said Andrew Mines, Watson-Marlow MD, “This exciting development is bringing us closer to our customers whose purpose is to help the world around us, from advancing cell and gene therapies through to ensuring people have access to clean drinking water. Together we will continue to develop market-leading fluid management solutions to engineer a more sustainable future. A huge thanks goes to the Watson-Marlow, BioPure, Americas and Watson-Marlow Central Support teams that are making this happen, as well as to our parent company, Spirax-Sarco Engineering who have enabled us to make such a significant investment in our future.”
The facility will reportedly create more than 150 positions, while production at the facility will mirror the company's European sites, ensuring continuity for customers. Completion of the facility is due in late 2022, with the first products due to be shipped from the site in late Q4.